- Home
Welcome !
We hope you enjoy your visit on the website of CHU Brugmann (Brugmann University Hospital), a member of the IRIS network and of the CHU of Brussels.
With its three complementary sites and 853 recognized beds, CHU Brugmann is one of the largest hospitals in Brussels. Its assets ? An ideal size to deploy all its activities and the best possible service, a strong social personality and a resolutely university character. Without counting an advanced technical environment and constant architectural improvements. Besides, CHU Brugmann remains one of the rare hospitals with pavilion structure in Europe.
- Virtual hospital
Three complementary sites
Quality labels
As a member of the Brussels public hospitals network IRIS, CHU Brugmann adheres to the patients' charter. It is certainly an additional guarantee to be well received...
Networks
- Departments
- Consultations
Appointments
If you can not come to your appointment, please let us know at least 24 hours in advance via Internet or via our free phone line : 0800/35.088.
- Hospitalization
- Education
- Research
The Brugmann Foundation is a non-profit organization created within the CHU Brugmann and mandated to develop and support scientific research and stimulate the development of new medical treatments...
- Last news
Guided tour of CHU Brugmann
Addresses, means of access and plans
Brugmann in numbers
Organization and flowcharts
Who's who ?
Contact us
Administrative and tech departments
Medical clinics and departments
Multidisciplinary departments
Nursing and paramedical department
Paramedical departments
Statuary and legal organs
Consultants and consultation hours
Online appointment request
Online appointment cancellation
Online information brochures
A foundation for research
List of ongoing clinical trials
Press releases
News headlines
Job vacancies
Description of the research protocol "CA2004004"
Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Relapsed or Refractory Multiple Myeloma (MM)
Phase III study| Status : Ongoing (but closed to recruitment)
Additional details
Indication (or studied pathology) : Hémato-onco
Brugmann identifier : CA2004004
EudraCT identifier :
2010-020347-12
ClinicalTrials.gov identifier : NCT01239797
Resources
Involved department : Hemato-oncology
Principal investigator : Efira
Sponsor : BMS
Contact : Clinical Research Unit
This protocol was approved by the UZ Gent ethics committee.
chu brugmann•Head office : Place A. Van Gehuchten 4 - 1020 Brussels
Page updated on 02/04/2019 (based on CRU data)